XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780 million for 2025, a year-on-year increase of over 193%. Net profit attributable to shareholders is expected to be no less than RMB 100 million, marking the first annual profit after turning a loss into a gain. Analysts noted that the strong 2025 results reflect the accelerating value realization of XTALPI's unique AI-driven drug development platform. In early 2026, the company secured partnerships with multiple industry leaders. It delivered automated and AI robotic laboratory solutions to chemical giant BASF and South Korea’s JW Pharmaceutical. Additionally, RTX-117, the first "AI+RNA" small-molecule innovative drug developed in collaboration with ReviR Therapeutics, completed its first patient dosing and entered clinical development. XTALPI also deepened cooperation with companies such as Dongyang Pharmaceutical, WeSheng Pharma, Yaotang Biotech, and Meda Biotech in specialized areas including endocrine drugs, mRNA therapies, and autoimmune diseases.